<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468351</url>
  </required_header>
  <id_info>
    <org_study_id>154342005</org_study_id>
    <nct_id>NCT00468351</nct_id>
  </id_info>
  <brief_title>Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)</brief_title>
  <acronym>IBEME</acronym>
  <official_title>Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravitreal triamcinolone has been effective for central macular thickness reduction and
      concomitant visual acuity improvement in patients with diabetic macular edema (DME). VEGF is
      a very effective inducer of permeability, being 50.000 times more potent than histamine, and
      may exert its effect on retinal vascular permeability by altering tight-junctions proteins,
      such as occluding and VE-cadherin. Based on these principles, there is a rationale for
      anti-VEGF agents treatment of increased retinal capillary permeability conditions, such as
      diabetic macular edema. Therefore, we conducted a randomized, prospective study to compare
      the efficacy and safety of intravitreal triamcinolone acetonide and intravitreal bevacizumab
      injection for refractory diffuse DME.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date>April 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central Macular Thickness, Best Corrected Visual Acuity</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure; lens status</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <condition>Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal Injection of 1,5 mg of bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal injection of 4 mg of Triamcinolone acetonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory diffuse DME (defined herein as clinically significant DME [by
             biomicroscopic evaluation] unresponsive to focal laser photocoagulation [performed at
             least 3 months before evaluation] and generalized breakdown of the inner blood-retina
             barrier with diffuse fluorescein leakage involving the foveal center and most of the
             macular area on fluorescein angiography),

          -  Snellen logarithm of minimum angle of resolution (LogMAR) BCVA equivalent of 20/40 or
             worse, and 3) central macular thickness (CMT) greater than 300µm on optical coherence
             tomography (OCT)

        Exclusion Criteria:

          -  Aphakic or pseudophakic eyes,

          -  Glycosylated hemoglobin (Hb A1C) rate above 10%,

          -  History of glaucoma or ocular hypertension,

          -  Loss of vision as a result of other causes,

          -  Systemic corticoid therapy,.

          -  History of thromboembolic event (including myocardial infarction or cerebral vascular
             accident);

          -  Major surgery within the prior 6 months or planned within the next 28 days;

          -  Uncontrolled hypertension (according to guidelines of the seventh report of the joint
             National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
             Pressure [JNC-7]);16

          -  Known coagulation abnormalities or current use of anticoagulative medication other
             than aspirin;

          -  Severe systemic disease; or

          -  Any condition affecting follow-up or documentation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Jorge, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>HCFMRP-USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rogério A Costa, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Retina Diagnostic and Treatment Division, Hospital de Olhos de Araraquara, Araraquara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo Jorge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCFMRP-USP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007 Apr;114(4):743-50.</citation>
    <PMID>17398322</PMID>
  </reference>
  <reference>
    <citation>Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3845-9.</citation>
    <PMID>16186372</PMID>
  </reference>
  <reference>
    <citation>Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007 Feb;27(2):141-9.</citation>
    <PMID>17290194</PMID>
  </reference>
  <reference>
    <citation>Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006 Nov-Dec;26(9):1006-13.</citation>
    <PMID>17151487</PMID>
  </reference>
  <reference>
    <citation>Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4569-78.</citation>
    <PMID>17003454</PMID>
  </reference>
  <reference>
    <citation>Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, Gaudric A, Massin P. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006 Nov;142(5):794-99. Epub 2006 Sep 15.</citation>
    <PMID>16978576</PMID>
  </reference>
  <reference>
    <citation>Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006 Oct;113(10):1706-12.</citation>
    <PMID>17011952</PMID>
  </reference>
  <reference>
    <citation>Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005 Oct;112(10):1747-57.</citation>
    <PMID>16154196</PMID>
  </reference>
  <reference>
    <citation>Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006 Nov-Dec;26(9):999-1005.</citation>
    <PMID>17151486</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2007</study_first_posted>
  <last_update_submitted>May 1, 2007</last_update_submitted>
  <last_update_submitted_qc>May 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2007</last_update_posted>
  <keyword>bevacizumab</keyword>
  <keyword>diabetes</keyword>
  <keyword>intravitreal</keyword>
  <keyword>macular edema</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

